| scholarly article | Q13442814 |
| P356 | DOI | 10.1191/026921601678320304 |
| P698 | PubMed publication ID | 12054149 |
| P2093 | author name string | G Zeppetella | |
| P2860 | cites work | Breakthrough pain: definition, prevalence and characteristics | Q33435886 |
| Sublingual absorption of selected opioid analgesics | Q34040004 | ||
| Cancer pain: pathophysiology and syndromes | Q35253535 | ||
| Drug delivery via the mucous membranes of the oral cavity | Q36272912 | ||
| Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study | Q39441138 | ||
| Sublingual morphine: efficacy reviewed | Q39444423 | ||
| Characterization of breakthrough pain by hospice patients and their caregivers | Q39444429 | ||
| Inhaled fentanyl as a method of analgesia | Q41237059 | ||
| Breakthrough pain: characteristics and impact in patients with cancer pain. | Q51089873 | ||
| Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. | Q51411890 | ||
| Severe episodic pain: management with sublingual sufentanil. | Q51666263 | ||
| [Pharmacokinetics of intranasal Fentanyl.]. | Q53022116 | ||
| P433 | issue | 4 | |
| P921 | main subject | fentanyl | Q407541 |
| P304 | page(s) | 323-328 | |
| P577 | publication date | 2001-07-01 | |
| P1433 | published in | Palliative Medicine | Q7127852 |
| P1476 | title | Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study | |
| P478 | volume | 15 |
| Q38226298 | Alternative routes to oral opioid administration in palliative care: a review and clinical summary. |
| Q37215376 | Assessment and management of breakthrough pain in cancer patients: current approaches and emerging research |
| Q47888494 | Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain |
| Q36916894 | Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet |
| Q24203830 | Fentanyl for chronic pain |
| Q24242219 | Fentanyl for chronic pain |
| Q37809847 | Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer |
| Q42230948 | Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain |
| Q44638919 | In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance |
| Q37154731 | Management of breakthrough pain in patients with cancer. |
| Q35095194 | Pharmacotherapy of cancer-related episodic pain |
Search more.